Research programme: thrombopoietin antibody mimetic - AlexionAlternative Names: Fab59
Latest Information Update: 16 Feb 2010
At a glance
- Originator Alexion Pharmaceuticals
- Mechanism of Action Thrombopoietin stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombocytopenia
Most Recent Events
- 01 Jun 2007 Preclinical trials in Thrombocytopenia in USA (Parenteral)